Malignant struma ovarii: Good response after thyroidectomy and 131I ablation therapy

Erica W.M. Janszen, Helena C. van Doorn, Patricia C. Ewing, Ronald R. de Krijger, Johannes H.W. de Wilt, Boen L.R. Kam, Wouter W. de Herder

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)


Background: Malignant struma ovarii is a rare malignant germ cell tumor of the ovary. Due to the rarity of this disease, treatment has not been uniform throughout the published literature.

Cases: We present three cases of malignant struma ovarii. Following primary surgery, all were subsequently treated with thyroidectomy and 131I ablation therapy, two patients as first line management, one following the occurrence of metastatic disease.

Conclusion: Histological diagnosis of malignant struma ovarii is similar to that of well differentiated thyroid carcinoma (WDTC). In line with the latest advice on treatment of WDTC, we believe that the best option for patients with malignant struma ovarii is surgical removal of the ovarian lesion followed by total thyroidectomy which allows the exclusion of primary thyroid carcinoma, and in addition, allows radioiodine (131I) ablation therapy for (micro) metastasis. After thyroidectomy, thyroglobulin can be used as a tumor marker for follow-up. Moreover, nuclear medicine imaging using radioiodine (123I) can be performed to demonstrate metastatic carcinoma. A multidisciplinary approach is essential.

Original languageEnglish
Pages (from-to)147-152
Number of pages6
JournalClinical Medicine: Oncology
Publication statusPublished - 29 Feb 2008
Externally publishedYes


  • Germ cell tumors
  • Malignant struma ovarii
  • Multidisciplinary approach
  • Radioiodine therapy
  • Thyroidectomy


Dive into the research topics of 'Malignant struma ovarii: Good response after thyroidectomy and 131I ablation therapy'. Together they form a unique fingerprint.

Cite this